Fig. 4

(A, B, and C) showcase images from a wound healing assay conducted at 0, 24, 48, and 72 hours following transfection with siPFKFB4, siHMOX1, and the chemotherapeutic agents DOX and TMZ in the U-87 MG cell line. The results indicate that silencing of PFKFB4 and HMOX1 mRNA through siPFKFB4 and siHMOX1 significantly hindered the migration of U-87 MG cells (magnification, X20). In panels (D, E, and F), bar charts quantify the extent of reduced migration in U-87 MG cells after silencing PFKFB4 and HMOX1 at the specified time points of 24, 48, and 72 hours post-transfection and treatment with DOX and TMZ. Statistical significance was determined using Student’s t-test, with data presented as mean ± SEM; significance levels are indicated as * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001 in comparison to the negative control group. Here, ‘NT’ refers to nontransfected cells, ‘NC’ denotes cells transfected with negative control siRNA, and ‘siPFKFB4’ and ‘siHMOX1’ indicate cells treated with specific siRNAs targeting PFKFB4 and HMOX1. Abbreviations used include: siRNA, small interfering RNA; U-87 MG, glioblastoma cell line; PFKFB4, 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4; HMOX1, heme oxygenase 1; DOX, doxorubicin; and TMZ, temozolomide.